查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1922400

日本潰瘍性大腸炎市場報告：按類型、疾病類型、分子類型、藥物類型、給藥途徑、分銷管道和地區分類（2026-2034年）

Japan Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2025年，日本潰瘍性大腸炎市場規模達3.638億美元。 IMARC Group預測，到2034年，該市場規模將達到5.682億美元，2026年至2034年的複合年成長率（CAGR）為5.08%。推動市場成長的主要因素包括日本潰瘍性大腸炎發病率的上升、醫療基礎設施的擴建和先進醫療技術的進步、研發活動的活性化、技術創新的加速以及醫療機構和患者支持團體加強宣傳活動。

潰瘍性大腸炎是一種發炎性腸道疾病，會損害大腸和直腸的內壁。症狀包括持續性腹瀉、直腸出血、腹痛、疲勞和體重減輕。潰瘍性大腸炎被認為是由環境因素、遺傳易感性和免疫反應過度共同作用引起的。診斷需要進行多項檢查，包括糞便檢驗、血液檢查、大腸鏡檢查和影像學檢查。潰瘍性大腸炎的治療方法包括抗發炎藥物、免疫抑制劑，以及在嚴重病例中可能需要手術治療。這些治療方法具有許多益處，包括緩解症狀、降低復發率、減少大腸直腸癌等併發症的風險。它們還能改善營養吸收和消化功能，進而提升患者的整體生活品質。此外，這些治療方法均有嚴謹的科學研究支持，能為患者帶來顯著的益處，包括長期緩解和減少住院需求。

日本潰瘍性大腸炎市場趨勢：

日本潰瘍性大腸炎盛行率的不斷上升是推動市場成長的主要因素之一。此外，高品質的醫療基礎設施和先進的醫療技術使得疾病的精準診斷和有效治療成為可能，為市場成長提供了廣闊前景。同時，在政府津貼和政策支持下，製藥業專注於新藥和新治療方法的研發，也促進了市場成長。此外，人工智慧（AI）等技術在診斷程序和數據分析中的應用，使得醫療服務提供者能夠制定個人化的治療方案，進一步推動了市場成長。遠距遠端醫療平台的日益普及，使得病患與醫師之間的互動更加頻繁且便捷，也進一步促進了市場成長。此外，醫療機構和病患權益組織所活性化的宣傳活動，可望提高民眾對潰瘍性結腸炎的認知，促進早期診斷，進而進一步推動市場成長。最後，日本人口老化加劇導致潰瘍性大腸炎發生率上升，也刺激了市場成長。此外，製藥公司與學術機構之間日益密切的合作正在推動藥物研發領域的創新，這對市場成長也產生了積極影響。因此，療效顯著、副作用更少、緩解期更長、住院次數更少的新型生物製藥的推出，正在推動市場成長。此外，各公司日益重視旨在改善長期治療效果的病患教育和依從性項目，也為國內市場帶來了豐厚的成長機會。

本報告解答的關鍵問題

  • 日本潰瘍性大腸炎市場目前發展如何？您認為未來幾年它將如何發展？
  • COVID-19 對日本潰瘍性大腸炎市場有何影響？
  • 日本潰瘍性大腸炎市場按類型分類的情況如何？
  • 日本潰瘍性大腸炎市場按疾病類型分類的市場區隔如何？
  • 日本潰瘍性大腸炎市場按分子類型分類的市場組成是什麼？
  • 日本潰瘍性大腸炎市場按藥物類型分類的市場組成是什麼？
  • 日本潰瘍性大腸炎市場如何根據給藥途徑進行細分？
  • 日本潰瘍性大腸炎市場按分銷管道分類的組成是怎樣的？
  • 日本潰瘍性大腸炎市場價值鏈的各個階段有哪些？
  • 日本潰瘍性大腸炎市場的主要促進因素和挑戰是什麼？
  • 日本潰瘍性大腸炎市場的結構是怎麼樣的？主要參與者有哪些？
  • 日本潰瘍性大腸炎市場的競爭程度如何？

目錄

第1章：序言

第2章：調查範圍與調查方法

  • 調查目標
  • 相關利益者
  • 數據來源
  • 市場估值
  • 調查方法

第3章執行摘要

第4章 日本潰瘍性大腸炎市場－引言

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭資訊

第5章 日本潰瘍性大腸炎市場概覽

  • 過去和當前的市場趨勢（2020-2025）
  • 市場預測（2026-2034）

第6章 日本潰瘍性大腸炎市場－按類型細分

  • 輕度潰瘍性大腸炎
  • 中度潰瘍性大腸炎
  • 重度潰瘍性大腸炎

第7章 日本潰瘍性大腸炎市場－依疾病類型細分

  • 潰瘍性直腸炎
  • 直腸乙狀結腸炎
  • 左側結腸炎
  • 全結腸炎或全結腸炎
  • 暴發性結腸炎

第8章：日本潰瘍性大腸炎市場－依分子類型細分

  • 低分子化合物
  • 生物製藥

第9章 日本潰瘍性大腸炎市場－依藥物類型細分

  • 抗發炎藥
  • 抗TNF生物製藥
  • 免疫抑制劑
  • Calcineurin抑制劑
  • 其他

第10章 日本潰瘍性大腸炎市場－依給藥途徑分類

  • 口服
  • 注射

第11章 日本潰瘍性大腸炎市場－依銷售管道分類

  • 醫院藥房
  • 零售藥房
  • 藥局
  • 其他

第12章 日本潰瘍性大腸炎市場－按地區分類

  • 關東地區
  • 關西、近畿地區
  • 中部地區
  • 九州和沖繩地區
  • 東北部地區
  • 中國地區
  • 北海道地區
  • 四國地區

第13章：日本潰瘍性大腸炎市場：競爭格局

  • 概述
  • 市場結構
  • 市場公司定位
  • 關鍵成功策略
  • 競爭對手儀錶板
  • 企業估值象限

第14章主要企業簡介

第15章 日本潰瘍性大腸炎市場：產業分析

  • 促進因素、限制因素和機遇
  • 波特五力分析
  • 價值鏈分析

第16章附錄

簡介目錄
Product Code: SR112026A19356

The Japan ulcerative colitis market size reached USD 363.8 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 568.2 Million by 2034 , exhibiting a growth rate (CAGR) of 5.08% during 2026-2034 . The increasing prevalence of ulcerative colitis in Japan, rising healthcare infrastructure and advanced medical technologies, growing research and development (R&D) initiatives, rapid technological advancements, and heightened public awareness initiatives by healthcare organizations and patient advocacy groups represent some of the key factors driving the market.

Access the full market insights report Request Sample

Ulcerative colitis refers to an inflammatory bowel disease that adversely affects the lining of the large intestine and rectum. It exhibits various symptoms, such as persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. Ulcerative colitis is suspected to be caused by a combination of environmental factors, genetic predisposition, and an overactive immune response. It is diagnosed through multiple tests, such as stool samples, blood tests, colonoscopy, and imaging studies. Ulcerative colitis is treated using anti-inflammatory medications, immunosuppressants, and, in more severe cases, surgical intervention. The treatments offer numerous benefits, including symptom relief, decreased frequency of flare-ups, and reduced risk of complications, such as colon cancer. They also improve the overall quality of life for patients by enabling better nutrient absorption and digestive function. Moreover, the therapies, backed by rigorous scientific research, provide patients with substantial advantages, such as long-lasting remission periods and a decreased need for hospitalization.

JAPAN ULCERATIVE COLITIS MARKET TRENDS:

The increasing prevalence of ulcerative colitis in Japan is one of the major factors contributing to the market growth. Moreover, the presence of a high-quality healthcare infrastructure and advanced medical technologies, allowing for precise diagnosis and effective management of the disease, is creating a positive outlook for the market growth. Additionally, the growing focus of the pharmaceutical industry on research and development (R&D) of new drugs and therapies, aided by government support in the form of grants and policies, is supporting the market growth. Along with this, rapid technological advancements, such as the integration of artificial intelligence (AI) in diagnostic procedures and data analytics, enabling healthcare providers to develop personalized treatment plans, are enhancing the market growth. In addition to this, the increasing adoption of telemedicine platforms, allowing for more frequent and convenient patient-doctor interactions, is bolstering the market growth. Besides this, the rising public awareness initiatives by healthcare organizations and patient advocacy groups, raising the profile of the disease and leading to earlier diagnosis, are anticipated to drive the market growth. Apart from this, the growing geriatric population in Japan, resulting in heightened incidences of ulcerative colitis, is also stimulating the market growth. Furthermore, the rising partnerships between pharmaceutical companies and academic institutions, fostering innovation in drug development and research, are positively influencing the market growth. In line with this, the introduction of new biologic drugs, offering effective results, fewer side effects, longer remission periods, and reduced hospital visits, are providing a thrust to the market growth. Moreover, the increasing focus by companies on patient education and compliance programs to improve long-term treatment outcomes is offering lucrative growth opportunities for the market across the country.

JAPAN ULCERATIVE COLITIS MARKET SEGMENTATION:

Type Insights:

  • To get detailed segment analysis of this market Request Sample
  • Mild UC
  • Moderate UC
  • Severe UC
  • Mild UC
  • Moderate UC
  • Severe UC

Disease Type Insights:

  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-sided Colitis
  • Pancolitis or Universal Colitis
  • Fulminant Colitis
  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-sided Colitis
  • Pancolitis or Universal Colitis
  • Fulminant Colitis

Molecule Type Insights:

  • Small Molecules
  • Biologics
  • Small Molecules
  • Biologics

Drug Type Insights:

  • Anti-Inflammatory Drugs
  • Anti-TNF Biologics
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others
  • Anti-Inflammatory Drugs
  • Anti-TNF Biologics
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others

Route of Administration Insights:

  • Oral
  • Injectable
  • Oral
  • Injectable

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Others
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Others

Regional Insights:

  • To get detailed regional analysis of this market Request Sample
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan ulcerative colitis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan ulcerative colitis market?
  • What is the breakup of the Japan ulcerative colitis market on the basis of type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of disease type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of molecule type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of drug type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of route of administration?
  • What is the breakup of the Japan ulcerative colitis market on the basis of distribution channel?
  • What are the various stages in the value chain of the Japan ulcerative colitis market?
  • What are the key driving factors and challenges in the Japan ulcerative colitis?
  • What is the structure of the Japan ulcerative colitis market and who are the key players?
  • What is the degree of competition in the Japan ulcerative colitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Ulcerative Colitis Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Ulcerative Colitis Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Ulcerative Colitis Market - Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Moderate UC
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Severe UC
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)

7 Japan Ulcerative Colitis Market - Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Proctosigmoiditis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Left-sided Colitis
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2020-2025)
    • 7.4.3 Market Forecast (2026-2034)
  • 7.5 Fulminant Colitis
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2020-2025)
    • 7.5.3 Market Forecast (2026-2034)

8 Japan Ulcerative Colitis Market - Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Biologics
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)

9 Japan Ulcerative Colitis Market - Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Forecast (2026-2034)
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Forecast (2026-2034)
  • 9.3 Immunosuppressant
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Forecast (2026-2034)
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Forecast (2026-2034)
  • 9.5 Others
    • 9.5.1 Historical and Current Market Trends (2020-2025)
    • 9.5.2 Market Forecast (2026-2034)

10 Japan Ulcerative Colitis Market - Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2020-2025)
    • 10.1.3 Market Forecast (2026-2034)
  • 10.2 Injectable
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2020-2025)
    • 10.2.3 Market Forecast (2026-2034)

11 Japan Ulcerative Colitis Market - Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Historical and Current Market Trends (2020-2025)
    • 11.1.3 Market Forecast (2026-2034)
  • 11.2 Retail Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Historical and Current Market Trends (2020-2025)
    • 11.2.3 Market Forecast (2026-2034)
  • 11.3 Drug Store
    • 11.3.1 Overview
    • 11.3.2 Historical and Current Market Trends (2020-2025)
    • 11.3.3 Market Forecast (2026-2034)
  • 11.4 Others
    • 11.4.1 Historical and Current Market Trends (2020-2025)
    • 11.4.2 Market Forecast (2026-2034)

12 Japan Ulcerative Colitis Market - Breakup by Region

  • 12.1 Kanto Region
    • 12.1.1 Overview
    • 12.1.2 Historical and Current Market Trends (2020-2025)
    • 12.1.3 Market Breakup by Type
    • 12.1.4 Market Breakup by Disease Type
    • 12.1.5 Market Breakup by Molecule Type
    • 12.1.6 Market Breakup by Drug Type
    • 12.1.7 Market Breakup by Route of Administration
    • 12.1.8 Market Breakup by Distribution Channel
    • 12.1.9 Key Players
    • 12.1.10 Market Forecast (2026-2034)
  • 12.2 Kansai/Kinki Region
    • 12.2.1 Overview
    • 12.2.2 Historical and Current Market Trends (2020-2025)
    • 12.2.3 Market Breakup by Type
    • 12.2.4 Market Breakup by Disease Type
    • 12.2.5 Market Breakup by Molecule Type
    • 12.2.6 Market Breakup by Drug Type
    • 12.2.7 Market Breakup by Route of Administration
    • 12.2.8 Market Breakup by Distribution Channel
    • 12.2.9 Key Players
    • 12.2.10 Market Forecast (2026-2034)
  • 12.3 Central/ Chubu Region
    • 12.3.1 Overview
    • 12.3.2 Historical and Current Market Trends (2020-2025)
    • 12.3.3 Market Breakup by Type
    • 12.3.4 Market Breakup by Disease Type
    • 12.3.5 Market Breakup by Molecule Type
    • 12.3.6 Market Breakup by Drug Type
    • 12.3.7 Market Breakup by Route of Administration
    • 12.3.8 Market Breakup by Distribution Channel
    • 12.3.9 Key Players
    • 12.3.10 Market Forecast (2026-2034)
  • 12.4 Kyushu-Okinawa Region
    • 12.4.1 Overview
    • 12.4.2 Historical and Current Market Trends (2020-2025)
    • 12.4.3 Market Breakup by Type
    • 12.4.4 Market Breakup by Disease Type
    • 12.4.5 Market Breakup by Molecule Type
    • 12.4.6 Market Breakup by Drug Type
    • 12.4.7 Market Breakup by Route of Administration
    • 12.4.8 Market Breakup by Distribution Channel
    • 12.4.9 Key Players
    • 12.4.10 Market Forecast (2026-2034)
  • 12.5 Tohoku Region
    • 12.5.1 Overview
    • 12.5.2 Historical and Current Market Trends (2020-2025)
    • 12.5.3 Market Breakup by Type
    • 12.5.4 Market Breakup by Disease Type
    • 12.5.5 Market Breakup by Molecule Type
    • 12.5.6 Market Breakup by Drug Type
    • 12.5.7 Market Breakup by Route of Administration
    • 12.5.8 Market Breakup by Distribution Channel
    • 12.5.9 Key Players
    • 12.5.10 Market Forecast (2026-2034)
  • 12.6 Chugoku Region
    • 12.6.1 Overview
    • 12.6.2 Historical and Current Market Trends (2020-2025)
    • 12.6.3 Market Breakup by Type
    • 12.6.4 Market Breakup by Disease Type
    • 12.6.5 Market Breakup by Molecule Type
    • 12.6.6 Market Breakup by Drug Type
    • 12.6.7 Market Breakup by Route of Administration
    • 12.6.8 Market Breakup by Distribution Channel
    • 12.6.9 Key Players
    • 12.6.10 Market Forecast (2026-2034)
  • 12.7 Hokkaido Region
    • 12.7.1 Overview
    • 12.7.2 Historical and Current Market Trends (2020-2025)
    • 12.7.3 Market Breakup by Type
    • 12.7.4 Market Breakup by Disease Type
    • 12.7.5 Market Breakup by Molecule Type
    • 12.7.6 Market Breakup by Drug Type
    • 12.7.7 Market Breakup by Route of Administration
    • 12.7.8 Market Breakup by Distribution Channel
    • 12.7.9 Key Players
    • 12.7.10 Market Forecast (2026-2034)
  • 12.8 Shikoku Region
    • 12.8.1 Overview
    • 12.8.2 Historical and Current Market Trends (2020-2025)
    • 12.8.3 Market Breakup by Type
    • 12.8.4 Market Breakup by Disease Type
    • 12.8.5 Market Breakup by Molecule Type
    • 12.8.6 Market Breakup by Drug Type
    • 12.8.7 Market Breakup by Route of Administration
    • 12.8.8 Market Breakup by Distribution Channel
    • 12.8.9 Key Players
    • 12.8.10 Market Forecast (2026-2034)

13 Japan Ulcerative Colitis Market - Competitive Landscape

  • 13.1 Overview
  • 13.2 Market Structure
  • 13.3 Market Player Positioning
  • 13.4 Top Winning Strategies
  • 13.5 Competitive Dashboard
  • 13.6 Company Evaluation Quadrant

14 Profiles of Key Players

  • 14.1 Company A
    • 14.1.1 Business Overview
    • 14.1.2 Services Offered
    • 14.1.3 Business Strategies
    • 14.1.4 SWOT Analysis
    • 14.1.5 Major News and Events
  • 14.2 Company B
    • 14.2.1 Business Overview
    • 14.2.2 Services Offered
    • 14.2.3 Business Strategies
    • 14.2.4 SWOT Analysis
    • 14.2.5 Major News and Events
  • 14.3 Company C
    • 14.3.1 Business Overview
    • 14.3.2 Services Offered
    • 14.3.3 Business Strategies
    • 14.3.4 SWOT Analysis
    • 14.3.5 Major News and Events
  • 14.4 Company D
    • 14.4.1 Business Overview
    • 14.4.2 Services Offered
    • 14.4.3 Business Strategies
    • 14.4.4 SWOT Analysis
    • 14.4.5 Major News and Events
  • 14.5 Company E
    • 14.5.1 Business Overview
    • 14.5.2 Services Offered
    • 14.5.3 Business Strategies
    • 14.5.4 SWOT Analysis
    • 14.5.5 Major News and Events

15 Japan Ulcerative Colitis Market - Industry Analysis

  • 15.1 Drivers, Restraints, and Opportunities
    • 15.1.1 Overview
    • 15.1.2 Drivers
    • 15.1.3 Restraints
    • 15.1.4 Opportunities
  • 15.2 Porters Five Forces Analysis
    • 15.2.1 Overview
    • 15.2.2 Bargaining Power of Buyers
    • 15.2.3 Bargaining Power of Suppliers
    • 15.2.4 Degree of Competition
    • 15.2.5 Threat of New Entrants
    • 15.2.6 Threat of Substitutes
  • 15.3 Value Chain Analysis

16 Appendix